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Abstract (311) 
Introduction 
Exacerbations of chronic obstructive pulmonary disease are characterised by increased symptoms such 
as dyspnoea, cough and sputum production and/or purulence, leading to greater risk of hospitalisation 
and mortality. Very few studies have measured long term trends in the  incidence of exacerbations of 
chronic obstructive pulmonary disease. We therefore investigated the incidence of moderate and 
severe exacerbations in the UK general population. 
Methods 
A population based-study including Clinical Practice Research Datalink (CPRD) patients ≥ 40 years of 
age with a current diagnosis of COPD within the United Kingdom from 2004 to 2013 was conducted. 
Individuals with a history of asthma were excluded from main analyses. We calculated the incidence 
rates for any, moderate, and severe exacerbations. Patients contributed time at risk from January 1st up 
to the date of the first outcome within each year. The incidence rate for any, moderate and severe 
exacerbations for COPD in each calendar year was calculated as follows: the sum of any or moderate 
or severe exacerbations for COPD in that year divided by the total duration of follow-up in the same 
calendar year from 2005 through to 2013.  We then analysed these rates by gender and age categories 
(40-59 years, 60-79 years and ≥80 years).  
Results  
Among 213,561 with incident COPD diagnosis, 86,300 patients were included in the study. From 
2005 to 2013, the incidence rate of any exacerbations increased from 89 to 98 per 1000 person years 
(PYs) (p=0.005). Women had significantly higher incidence rates of any exacerbation for each 
calendar year when compared to men (p<0.0001). The incidence rate of any and moderate 
exacerbations increased with age from 2005 to 2007. For severe exacerbations incidence decreased 
from 2005 to 2007 before increasing from 2008 until the end of follow-up (43 per 1000 PYs (95% 
confidence interval, 42-45/1000PYs) in 2013). Incidence rates of severe exacerbations were similar by 
gender and patients aged 80+ years had a higher incidence rate of severe exacerbation from 2005 to 
2008 after which their incident rate dropped in subsequent years. 
Conclusion 
This is the first study that reports the long-term changes in the incidence rates of moderate and severe 
exacerbations within the UK general practice. Women showed a substantially higher risk of any 
COPD exacerbations, and their risk is increasing. The incidence rates of any exacerbations increased 
during the study period, while severe exacerbations were variable. Furthermore, incidence rates varied 
substantially by age group. 
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Introduction (313)  
 
Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as acute episodes of 
increased respiratory symptoms necessitating additional therapy [1]. Main symptoms are increased 
dyspnea, cough and sputum production and/or purulence. Exacerbations of COPD negatively impact 
on lung function [2] health status [3] and muscle function [4]. Also, they are important drivers of 
hospitalisations [5] and are associated with high mortality risk [6]. Hence, prevention of exacerbations 
of COPD is one of the main goals of pharmacologic treatment of the disease and multiple options for 
drug therapy are available [7]. In the United Kingdom (UK), £253 million British Pounds (GBP) is 
spent yearly on COPD management, with more than 50% of the costs attributed to exacerbations [8]. 
Also, COPD-related mortality has increased from 2004-2012 (̴29, 000 died in 2012) while incidence of 
COPD decreased and then remained stable over the same period (̴115, 000 new diagnosed COPD in 
2012). There are over a million bed days and 140,000 hospital admissions each year in the UK due to 
COPD (1.7% of all hospital admissions and bed days) [9].   
The role of demographic characteristics in shaping the trends in exacerbations and related 
hospitalisations over time has not been adequately described in a UK population. Understanding trends 
in acute exacerbations and related hospitalisations can help redirect healthcare policies and 
interventions to subgroups most affected by Exacerbations of COPD , allow comparison between 
countries to aid healthcare planning, predict future healthcare challenges, and provide a basis for 
improving future management. Thus, there is a need to understand the constantly changing trends and 
to subsequently target health planning and policies towards groups who are at high risk of 
exacerbations of COPD [10]. Management of patients with COPD in the UK is performed mainly 
within the primary care setting [11].  Therefore this study aims to describe the incidence rates of 
moderate and severe exacerbations for COPD by age and gender within the UK primary care setting 
from 2005-2013. 
 
 
 
 
 
 
 
 
 
5 
 
 
Methods (726) 
Data source 
This study was conducted with data from the Clinical Practice Research Datalink (CPRD), formerly 
known as the General Practice Research Database (GPRD). CPRD contains computerized medical 
records of 674 primary care practices in the UK. Data collection started in January 1987 and over 11 
million persons are currently included, corresponding with 7% of the UK population [12]
,
[13]. The 
introduction of the Quality and Outcomes Framework (QOF) in April 2004, was aimed at facilitating 
quality reporting of various diseases by GPs, including COPD and its related outcomes [14]. The 
quality management system uses indicators recorded by GPs to monitor effectiveness in COPD 
reporting and to reduce the rate of misdiagnosis. Indeed, a high positive predictive value in identifying 
patients with COPD based on these read codes has been reported [12] and the CPRD has been used in 
various studies on COPD [15–17]. Using CPRD ensured that our results are generalizable within the 
UK population. The independent scientific advisory committee of the Medicines and Healthcare 
product Regulatory Agency (MHRA) database research approved this study. (ISAC protocol No: 
18_046R). 
 
Study population 
We selected all patients aged 40 years with a diagnosis of COPD as recorded by read codes within 
the CPRD. The study period was from 1
st
 January 2004 until 31
st
 December 2013 corresponding to the 
period since the introduction of the Quality and Outcomes Framework (QOF). However, we calculated 
the incidence rates from 2005 through to 2013. For the main analyses, we excluded all patients with a 
history of asthma from the study and COPD diagnosis prior to 2004. Follow-up ended at the earliest of 
the study end date (31
st
 December 2013), or the patient’s death or transfer out of the practice. The 
primary endpoint was the first acute exacerbation of COPD in a given calendar year, identified using 
validated read codes for exacerbations of COPD [18] from the referral and/or clinical files. We defined 
this as any exacerbations of COPD. The secondary outcomes were defined as follows: (i) 
exacerbations of COPD without hospitalisations/accident and emergency (A&E) visits evaluated using 
validated Read codes for exacerbations of COPD from the clinical file only. This was defined as 
moderate exacerbations of COPD. (ii) COPD-related hospitalisations/A&E visit evaluated using Read 
codes for hospitalisation/A&E visits for COPD from both clinical and/or referral file in addition with 
validated read codes for exacerbations of COPD from the referral file. This was defined as severe 
exacerbations of COPD. Referral files contains referral details recorded by GPs while the clinical file 
contains all the medical history data entered by the GP.[19] 
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Statistical analysis 
For our main analyses we only counted the first outcome of interest within a given calendar year (i.e. 
patients with an outcome only contributed time at risk from January 1
st
 up to the date of the first 
outcome within each year). The incidence rates for moderate/severe, moderate and severe 
exacerbations for COPD in each calendar year was calculated as follows: the sum of any or moderate 
or severe exacerbations for COPD in that year divided by the total duration of follow-up in the same 
calendar year. We only calculated incidence rates from 2005 through to 2013. The incidence rates 
were expressed as the number of exacerbations per 1000 person-years (PY). We then analysed these 
rates by gender and age categories (40-59 years, 60-79 years and 80 years). The incidence rates are 
accompanied by 95% confidence intervals (CI). Using chi-square test, we compared the changes in 
trends with statistically significant difference determined at p<0.05 between calendar year, gender and 
age categories. All analyses were carried out using SAS 9.4 (SAS Institute, Cary, NC). 
 
Sensitivity analysis 
We performed two sensitivity analyses. As far as we know, there are no established methods to 
estimate incidence rates of moderate and severe exacerbations among COPD patients. In the first 
sensitivity analysis we no longer counted the first event within a given calendar year, but we added up 
all exacerbations that occurred in a calendar year. To overcome the problem of potentially counting 
the same event more than once, we stipulated a gap of at least 30 days between consecutive events of 
any exacerbations of COPD. This sensitivity analysis was carried out to depict the overall trend of any 
exacerbations of COPD using validated read codes form referral or/and clinical files (see 
supplementary appendix: eTable1).  In the second sensitivity analysis, we included patients with a 
history of asthma and estimated the incidence rates of any exacerbations taking only the first 
exacerbation into consideration. (see supplementary appendix: eTable2).   
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Results (685) 
We identified 213,561 patients with COPD diagnosis within the CPRD of whom 86,300 met the 
inclusion criteria. The mean age of patients in our study was 68 years and 45.5% (n=39,241) were 
women (see supplementary appendix: eTable 1). 
 
Trends of any exacerbations for COPD 
We observed 30,996 any exacerbation for COPD during the study period. Table 1 shows the overall 
incidence rates of any exacerbations for COPD. From 2005 to 2007, the incidence rate of the primary 
any exacerbations remained stable at around 88 per 1000PYs. A rise in incidence rate of any 
exacerbations was noted from 2008 to 2012 (112 per 1000PYs (95%CI, 109-114/1000PYs)). 
However, we observed a decrease in the incidence of any exacerbations to 98 per 1000 PYs in 2013. 
Overall, there was a 10% increase in any exacerbations from 2005 to 2013, which was statistically 
significant (p=0.005). Gender specific incidence rates are shown in Figure 1a. In both men and 
women, any exacerbations incidence rates followed a somewhat similar pattern of year-to-year 
change. The incidence rates for both men and women increased from 84 and 95 in 2005 to 90 and 107 
per 1000 PYs in 2013 respectively. Women had greater incidence rates of any exacerbations in each 
calendar year compared to men (p<0.0001). 
Figure 2a shows the incidence rates of any exacerbations by age. There was an increasing incidence 
rate of any exacerbations with increasing age group from 2005 to 2007, which disappeared from 2009 
to 2013. In 2008 the incidence rates of any exacerbations were the same among patients 40-59 and 60-
79 years old.  We observed a decrease in year-to-year incidence rates of any exacerbations for 80+ 
year-old patients. In contrast, any exacerbation rates increased across the study period for patients in 
the 40-59 and the 60-79 year old age groups.  
 
Trends of moderate exacerbations for COPD 
From 2005 until 2013, a total of 30,973 moderate exacerbations were observed in our study 
population. Table 2 shows the annual incidence rates of moderate exacerbations for COPD. The 
general trend of moderate exacerbation was similar to that of any exacerbations for COPD by age and 
gender (see appendix). From 2005 to 2007, the incidence rate of the moderate exacerbations remained 
stable at around 88 per 1000PYs before increasing to 112 per 1000 PYs (95%CI, 109-114/1000PYs) in 
2012. We found a significant increase in moderate exacerbations for COPD by 10% from 2005 to 
2013 (p=0.005). 
 
Trends of severe exacerbations for COPD 
Between 2005 and 2013 we found 8032 severe COPD exacerbations. From 2005 to 2007 we found a 
decline in the incidence of severe exacerbations for COPD from 18 to 11 per 1000 PYs. However, 
there was a steady increase from 2008 until the end of the study period. In 2013, the incidence rate was 
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43 per 1000 PYs. Figure 1b shows the incidence rates of severe exacerbations by gender (Table 3). 
Similar to the overall trend, both men and women showed a flattened ‘U’ shaped decrease in 
hospitalisation/A&E incidence rates before an increase from 2008 to their peak rates in 2013.  Women 
and men had similar incidence rates in each calendar year of the study (p=0.747).  
Figure 2b shows the incidence rates of severe exacerbations for COPD by age. We noticed an 
increasing incidence rate of severe exacerbations for COPD by age from 2005 to 2008. In 2012 and 
2013 patients aged 60-79 years had a significantly higher incidence rate compared to other age groups 
(p<0.0001). For each age group, the incidence rates for severe exacerbations decreased from 2005 to 
2007 before increasing from 2008 to 2013 (Figure 2b). For all age groups, the rates in 2009 were 
similar. 
 
Sensitivity analysis of trends of any exacerbations of COPD.  
For the first sensitivity analysis we considered multiple events in a given calendar year. A total of 
37,160 any exacerbations of COPD were observed during the study period. The trends were similar to 
that observed for moderate/severe exacerbations of COPD when we evaluated only one event in a 
calendar year. However, we found a non-significant increase of 3% in the incidence rates of any  
COPD exacerbations from 2005 to 2013. (see supplementary appendix: eTable2). In the second 
sensitivity analysis we included patients with a history of asthma. The incident rates declined 
gradually until 2007 and remained the same from 2008 to 2009. The incident rates dropped from 119 
to 103 per 1000 PYs from 2011 to 2013. Overall, there was a 2% decrease in the incidence rates of any 
COPD exacerbations, which was not statistically significant (p=0.577). (see supplementary appendix: 
eTable3). 
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Discussion (1380) 
Summary of main findings 
Using the world’s largest primary care database, this study showed a significant increase in the 
incidence rates from 2005 to 2013 for the primary endpoint, any exacerbations of COPD. For severe 
exacerbations, incidence rates increased from 2008 to 2013. Women had higher incidence rates of any 
exacerbations compared to men patients throughout the study period but they had similar incidence 
rates of severe exacerbations for COPD from 2005 to 2013. The incidence rate of any exacerbations 
for COPD was higher in patients 80+ years from 2005 to 2008, after which this trend was not 
observed.  
 
Comparison with existing literature 
To the best of our knowledge there has been no previous large-scale population based studies on the 
trends of moderate to severe exacerbations of COPD in the UK.  Previous studies have focused mainly 
on prevalence rates of COPD [20–22] with no emphasis on the trends of acute exacerbations of 
COPD. Using the Health Improvement Network database, Snell et al [9] reported a 27% increase in 
the prevalence of COPD in the UK from 2004 to 2012. This increase in prevalence of COPD is 
correlated with the increase  in incidence of  moderate and severe exacerbations of COPD in our study. 
A study conducted among 423 COPD patients within the Dutch general practice from 1980 to 2006 
reported a reduction in overall annual exacerbation rates which is contrary to our findings[10]. The 
study also observed that the decreasing trends was independent of age and sex [10]. It is difficult to 
draw a definite conclusion for the declining trends of acute exacerbations of COPD in their study, but 
it might be related to changes in treatment guidelines for COPD and increased emphasis on 
vaccination during the study period [10]. In our study, we also found that the incidence rates of acute 
exacerbations increased with increasing age in certain years. This might be due to disease progression 
and severity of the disease state. Investigators have reported a relationship between age and 
underreporting of acute exacerbations [23], which means that the incidence rates might be 
underestimated among older patients.  
Although, few studies have focused on incidence rates of moderate exacerbations of COPD more have 
focused on COPD exacerbation requiring hospitalisations (severe exacerbations). Furhrrmal et al [24], 
examined the temporal trends in acute exacerbations related hospitalisation from 1998 to 2007 in 
France, and found that admission rates increased significantly, especially among females. Although, 
our study also reported an increase in severe exacerbations there was only slight differences by gender 
for all years. Another study conducted in Brazil found no changes in hospitalisation rates from 1998 to 
2009 [25]. The Hospital Episode Statistics published by the UK department of health from 1998 to 
2003 showed an increase in the number of admissions for COPD [26], with 140,000 hospital 
admissions each year [9] . It has been reported that 30% of patients hospitalised for exacerbations will 
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be seen again and possibly admitted with another exacerbation within 8 weeks [26]. Contrary to our 
findings, a study investigating the incidence of COPD which defined COPD diagnosis based on A&E 
visit and hospitalisation in Canada reported a reduction in the incidence of COPD from 1996 to 2007 
[20]. Similarly, Kinnula et al [27] reported a decrease in the rates of hospitalisations associated with 
COPD in Finland from 1998 to 2007. The exact reason for the low incidence rates of severe 
exacerbations in our study is not completely understood. However, this might be related to the fact that 
most COPD patients die from various fatal comorbidities associated with COPD severity before they 
could be hospitalised for an acute exacerbations of COPD [28]. Another explanation is that many 
patients have problems in identifying symptom aggravation and fail to report exacerbations to health 
experts [29,30], resulting in spontaneous hospitalisations and A&E visits. Additionally, GPs often 
record COPD hospitalisation using less specific read codes. [31]. Merinopoulou et al [32], reported 
that the rates of COPD-related hospitalisations from 2011 to 2013 were higher in patients with more 
severe disease state, with most severe patients  (GOLD D) having 3 times the number of exacerbations 
compare to least severe groups (GOLD A). The lack of information on disease stage in our study made 
it impossible to corroborate their finding. 
 
Whilst emphasis has been on adherence to treatment guidelines among COPD patients in different 
GOLD guidelines as a means of reducing prevalence of COPD-related exacerbations, a significant 
dissociation has been reported between adherence to guidelines and actual management of COPD 
patients [33]. A study conducted among 24,957 COPD patients in the UK showed that the patients 
were not managed in accordance to GOLD and National Institute for Health and Care Excellence 
recommendations, with substantial amount of patients not receiving appropriate medications [34]. 
Despite current developments with LAMA/LABA and ICS in treatment of COPD patients we found 
no objective reduction in exacerbations in our study. Although, low adherence to therapy [35], and 
improper inhaler technique among COPD patients [7] may have contributed to the trend observed. 
Furthermore variation in the incidence of exacerbations seems to follow the incidence of influenza A 
during the study period, suggesting that this might have had an impact our study [36]. It is also 
important to note that the use of long acting agents was low in our study cohort. 
 
Strengths and limitations 
A major strength of this study was the inclusion of patients from one of the world’s largest primary 
care databases, thus providing a very large sample size. Second, we were able to assess the incidence 
rates of moderate and severe exacerbations over a long period. Third, we consider periods since the 
introduction of the QOF ensuring greater quality and validity of data recording. Fourth, we used 
validated read codes for acute exacerbations of COPD. Lastly, a validity study of COPD patients in the 
CPRD concluded that patients with COPD can be identified easily using specific read codes [37]. 
Despite the numerous strengths, this study had some limitations. The use of the read codes for acute 
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exacerbation may have underestimated the true incidence rates of COPD exacerbations. However, the 
read codes used have been reported to have a high positive predictive value (PPV) of 96% in 
identifying patients with COPD exacerbation in the CPRD [18] and we explored both clinical and 
referral files to ensure all exacerbations were identified. Nevertheless, we may have missed a 
considerable amount of exacerbations that may be miscoded e.g. as respiratory tract infections or 
pneumonia. Although we excluded asthma patients from the main analyses, it was impossible to rule 
out the inclusion of patients with reversible airflow limitation in this study [38]. Furthermore, the PPV 
of approximately 50.2% and a sensitivity of 5.4% in identifying hospitalisations for COPD within the 
CPRD is arguably low, which may have resulted from GPs recording hospitalisation for COPD by 
generic hospitalisation codes and/or acute exacerbation read codes [31]. As such the incidence rate for 
severe exacerbations is likely to an underestimate of the true incidence in the UK. While the method of 
diagnosis of COPD has not changed since 2005, GPs ability to identify exacerbations of COPD might 
have changed over time [32], which may have had an effect on our findings. 
 
Implication for future research and clinical practice 
The introduction of QOF in 2004 was aimed at ensuring quality recording of diagnosis and treatment 
of COPD and other chronic diseases [39]. Although, approximately equal numbers of patients were 
diagnosed with COPD annually during the study period. The higher incidence rates of any 
exacerbations among women and among older patients suggests emphasis be placed on adherence to 
treatment guidelines and other interventions among these patient groups. The increased incidence of 
any exacerbations in our study since the introduction of QOF is concerning. This coincides with 
sceptics questioning the relevance of QOF in aiding holistic clinical care [39], although it cannot be 
denied that its introduction has resulted in a modest reduction in overall emergency admission rates for 
long-term conditions [39]. ECLIPSE investigators, suggest that patients with two or more 
exacerbations in a year represent a distinct “frequent exacerbators” phenotype, and have increased risk 
of future exacerbation events [40]. Though these group of patients could not be identified in our study.  
Fundamentally, it is important for GPs to identify these patients by carefully exploring patient’s 
history and targeting interventions based on recommendations from clinical guidelines. Also a greater 
emphasis should be made on treatment adherence by COPD patients, as “frequent exacerbators” and 
patients with history of hospitalisation have been reported to be less likely to adhere to therapy [35]. 
 
Conclusion 
This is the first study that reports the long-term changes in the incidence rates of moderate and severe 
exacerbations as recorded by UK general practitioners. Women showed a substantially higher risk of 
any COPD exacerbations, and their risk is increasing. The incidence rates of any exacerbations 
increased during the study period, while severe exacerbations were variable. Furthermore, incidence 
rates varied substantially by age group. In addition, these findings have the potential to help redirect 
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healthcare policies, planning and interventions to target subgroups more effectively, and may provide 
a basis for improving overall COPD management in the future.  
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Results 
Table 1. Incidence rates* of any exacerbations for COPD from 2005-2013
¶
 
Year No. of any exacerbations 
n=30996 
PY at risk IR /1000 PY (95% CI) 
2005 1110 12514.4 89 (84-95) 
2006 1678 18981.8 88 (84-93) 
2007 2194 24905.1 88 (85-92) 
2008 2838 30441.4 93 (90-97) 
2009 3356 35161.5 95 (92-99) 
2010 4315 40319.5 107 (104-110) 
2011 4839 44777.5 108 (105-111) 
2012 5500 49260.1 112 (109-114) 
2013 5166 52893.7 98 (95-100) 
* Only one event per calendar year was counted. 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; A&E, accident & emergency; 
PY, person-years; CI, confidence interval. 
¶
 using validated read codes for AECOPD from clinical and/or referral files. 
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Table 2. Incidence rates* of moderate exacerbations for COPD from 2005-2013
¶
 
Year No. of moderate exacerbations 
n=30973 
PY at risk IR /1000 PY (95% CI) 
2005 1110 12514.8 89 (84-94) 
2006 1676 18983.3 88 (84-92) 
2007 2193 24905.2 88 (85-92) 
2008 2835 30443.4 93 (90-96) 
2009 3352 35164.4 95 (92-98) 
2010 4313 40320.7 107 (104-110) 
2011 4835 44779.7 108 (105-111) 
2012 5496 49261.5 112 (109-114) 
2013 5163 52895.7 98 (95-100) 
* Only one event per calendar year was counted. 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; A&E, accident & emergency; 
PY, person-years; CI, confidence interval. 
¶
 using validated read codes for AECOPD from clinical file only. 
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Table 3. Incidence rates of severe exacerbations for COPD  from 2005-2013
¶
 
Year No. of  severe exacerbations* 
n=8032 
PY at risk IR /1000 PY (95% CI) 
2005 229 12896.0 18  (16-20) 
2006 248 19646.9 13 (11-14) 
2007 277 25792.1 11 (10-12) 
2008 455 31421.6 14 (13-16) 
2009 556 36382.1 15 (14-17) 
2010 821 41713.3 20 (18-21) 
2011 1224 46192.4 26 (25-28) 
2012 1902 50388.8 38 (36-39) 
2013 2320 53691.0 43 (42-45) 
* Only one event per calendar year was counted. 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; A&E, accident & emergency; 
PY, person-years; CI, confidence interval. 
¶
 using read codes for hospitalisation/A&E visits for COPD from clinical and/or referral files in addition with validated read codes for AECOPD from 
referral file. 
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               Figure 1.  Incident rates of (a) any exacerbations 
¶
  or (b) severe exacerbations
*
  for COPD by gender. 
    Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; A&E, accident & emergency; PY, person-years. 
    ¶ using validated read codes for AECOPD from clinical and/or referral files. 
    * using read codes for hospitalisation/A&E visits for COPD from clinical and/or referral files in addition with validated read codes for AECOPD from referral file. 
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        Figure 2.  Incident rates of (a) any exacerbations 
¶
 or (b) severe exacerbations
*
  for COPD by age. 
    Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; A&E, accident & emergency; PY, person-years. 
    ¶ using validated read codes for AECOPD from clinical and/or referral files. 
    * using read codes for hospitalisation/A&E visits for COPD from clinical and/or referral files in addition with validated read codes for AECOPD from referral file. 
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 Supplementary appendix  
This appendix forms part of the original submission.  
Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 
2013.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               eFigure 1: Flow chart showing the selection of eligible patients 
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Patients with history of asthma 
n=46,758 
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eTable1: Baseline characteristics COPD patients (n=86,300) 
 n (%) 
Females 39,241 45.5 
Mean age (years, SD) 68.1 11.3 
Age category (years)   
  40-59 19,475 22.6 
  60-79 51,982 60.2 
  80+ 14,843 17.2 
BMI (kg/m
2
) in the past 6 months   
 Underweight (BMI < 18.5 kg/m
2
) 4,784 5.5 
 Normal weight (BMI 18.5-24.9 kg/ m
2
) 29,808 34.5 
 Overweight (BMI 25.0-29.9kg/ m
2
) 26,529 30.7 
 Obese (BMI ≥ 30,0 kg/ m2) 20,938 24.4 
 Missing 4,241 4.9 
Smoking status at index date   
 Never 9,005 10.4 
 Current 38,207 44.3 
 Former  38,662 44.8 
 Missing 426 0.5 
Drug use (in the past 6 months)   
 SABAs 48,624 56.3 
 LABAs 7,542 8.7 
 SAMAs 7,576 8.8 
 LAMAs 15,102 17.5 
 Xanthine derivatives 770 0.3 
 Antidepressants 17,063 19.8 
History of co-morbidities    
 Diabetes Mellitus 9,619 11.1 
 Anxiety 12,267 14.2 
 Osteoporosis 15,063 5.9 
 Malignancies excluding non-melanoma skin cancer 12,357 14.3 
 Chronic liver disease 292 0.3 
 Ischaemic heart disease 12,493 14.5 
Abbreviations: SD, standard deviation; COPD, chronic obstructive pulmonary disease; BMI, body 
mass index; SABAs, short-acting beta-2 agonists; LABAs, long-acting beta-2 agonists; SAMAs, 
short-acting muscarinic antagonists; LAMAs, long-acting muscarinic antagonists; ICS, inhaled 
corticosteroids. 
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eTable 2. Incidence rates* of any exacerbations for COPD from 2005-2013
¶
 
Year No. of any exacerbations 
n=30996 
PY at risk IR /1000 PY (95% CI) 
2005 
1471 13350.9 110 (105-116) 
2006 
2260 20607.8 109 (105-114) 
2007 
3034 27540.5 110 (107-114) 
2008 
3934 34209.7 114 (112-118) 
2009 
4760 40181.9 118 (115-122) 
2010 
6247 46885.5 133 (130-136) 
2011 
7137 52995.1 134 (132-138) 
2012 
8090 59217.2 137 (134-139) 
2013 
7250 64304.4 113 (110-115) 
*  We counted all events occurring 30 days between consecutive events within a calendar year. 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; A&E, accident & emergency; 
PY, person-years; CI, confidence interval. 
¶
 using validated read codes for AECOPD from clinical and/or referral files. 
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eTable 3. Incidence rates* of any exacerbations for COPD from 2005-2013 among COPD patients with history of asthma
¶
 
Year No. of any exacerbations 
n=53514 
 
PY at risk IR /1000 PY (95% CI) 
2005 2098 19984.5 105 (101-109) 
2006 3100 30311.7 102 (99-106) 
2007 4082 39632.7 103 (100-106) 
2008 5106 48203.1 106 (103-109) 
2009 5858 55284.1 106 (103-109) 
2010 7390 63121.3 117 (115-120) 
2011 8273 69617.8 119 (116-121) 
2012 9204 76043.7 121 (119-123) 
2013 8403 81196.9 103 (101-106) 
* Only one event per calendar year was counted. 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; A&E, accident & emergency; 
PY, person-years; CI, confidence interval. 
¶
 using validated read codes for AECOPD from clinical and/or referral files. 
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eTable 4. Incidence rates of any exacerbations of COPD from 2005-2013 by gender
¶
 
 Men Women 
Year No of any exacerbations 
n=15609 
 
PY at risk IR /1000 PY  
 
No of any exacerbations 
n=15387 
 
PY at risk IR /1000 PY  
2005 579 6902.9 84 (78-91)  531 5611.5 95 (87-103) 
2006 856 10465.5 82 (77-87)  822 8516.2 97 (90-103) 
2007 1132 13676.2 83 (78-88)  1062 11228.9 95 (89-100) 
2008 1487 16628.7 89 (85-93)  1351 13812.7 98 (93-103) 
2009 1698 19195.5 88 (85-93)  1658 15966.0 104 (99-109) 
2010 2154 21933.4 98 (94-102)  2161 18386.1 118 (113-122) 
2011 2451 24244.7 101 (97-105)  2388 20532.8 116 (112-121) 
2012 2700 26598.9 102 (98-105) 2800 22661.1 124 (119-128) 
2013 2552 28494.1 90 (86-93) 2614 24399.5 107 (103-111) 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; PY, person-years. 
¶
 using validated read codes for AECOPD from clinical and/or referral files 
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eTable 5. Incidence rates of moderate exacerbations of COPD from 2005-2013 by gender
¶
 
 Men Women 
Year No of moderate 
exacerbations   
n=15599 
PY at risk IR /1000 PY  
 
No of moderate 
exacerbations 
n=15374 
PY at risk IR /1000 PY  
2005 579 6903.4 84 (78-91) 531 5611.5 95 (87-103) 
2006 856 10465.6 82 (77-87)  820 8517.7 96 (90-103) 
2007 1132 13676.2 83 (78-88) 1061 11229.1 94 (89-100) 
2008 1485 16630.6 89 (85-94) 1350 13812.8 98 (93-103) 
2009 1697 19195.8 88 (84-93)  1655 15968.5 104 (99-108) 
2010 2152 21934.6 98 (94-102) 2161 18386.1 118 (113-122) 
2011 2450 24245.1 101 (97-105) 2385 20534.6 116 (112-121) 
2012 2698 26599.4 101 (98-105) 2798 22662.1 124 (119-128) 
2013 2550 28495.4 90 (86-93) 2613 24400.3 107 (103-111) 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; PY, person-years. 
¶
 using validated read codes for AECOPD from clinical file only 
27 
 
 
 
eTable 6. Incidence rates of severe exacerbations of COPD from 2005-2013 by gender
¶
 
 Men Women 
Year No of severe 
exacerbations 
n=4318 
PY at risk IR /1000 PY  
 
No of   severe 
exacerbations 
n=3714 
PY at risk IR /1000 PY  
2005 119 7108.1 17  (14-20) 110 5787.9 
19 (16-23) 
2006 115 10811.4 11 (9-13) 133 8835.5 15 (13-18) 
2007 149 14116.3 11 (9-12) 128 11675.8 11 (9-13) 
2008 238 17150.8 14 (12-16) 216 14270.9 15 (13-17) 
2009 299 19806.7 15 (13-17) 258 16575.4 16 (14-18) 
2010 467 22577.2 21 (19-23) 354 19136.1 18 (17-21) 
2011 656 24941.7 26 (24-28) 568 21250.8 27 (25-29) 
2012 1029 27054.8 38 (36-40) 873 23334.1 37 (35-40) 
2013 1246 28788.9 43 (41-46) 1074 24902.7 43 (41-46) 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; PY, person-years. 
¶
 using read codes for hospitalisation/A&E visits for COPD from clinical and/or referral files in addition with validated read codes for AECOPD from referral 
file. 
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